Archit Organosys reported a 59% year-on-year increase in net profit to ₹803.21 lakh for the fiscal year ended March 31, 2026, compared to ₹505.11 lakh in FY25.

The Ahmedabad-based specialty chemicals manufacturer saw total income rise by 11.77% to ₹14,383.71 lakh from ₹12,869.20 lakh in the previous fiscal. Revenue from operations specifically grew to ₹14,095.25 lakh from ₹12,559.92 lakh.

Financial Performance

Profit before tax reached ₹1,099.25 lakh, up significantly from ₹753.89 lakh in FY25. The company maintained steady operational costs while managing financial expenses effectively.

Financial expenses decreased to ₹228.82 lakh from ₹257.98 lakh, contributing to the improved bottom line. Depreciation and amortization expenses remained stable at ₹601.44 lakh.

Dividend Recommendation

The Board of Directors recommended a final dividend of ₹1 per equity share of face value ₹10 each for FY26, representing a 10% payout ratio. This is subject to shareholder approval at the 33rd Annual General Meeting scheduled for September 30, 2026.

What the Numbers Show

The divergence between revenue growth and profit expansion highlights improved operational leverage. While top-line growth stood at 11.77%, net profit surged nearly six times faster at 59%. This acceleration was supported by a reduction in financial expenses of ₹29.16 lakh and controlled operating costs, which grew at a slower pace than revenue. The effective tax rate also moderated to 26.93% from 33% in the previous year, further boosting bottom-line retention.

Corporate Governance Updates

Kandarp K. Amin retires by rotation at the upcoming AGM but offers himself for re-appointment as Chairman and Whole-Time Director. The meeting will also seek approval for related-party transactions with Archit Life Science Limited, including loans up to ₹75 crore and trade transactions up to ₹100 crore annually for FY27 and FY28.

The company plans to acquire a 67.44% stake in Archit Life Science Limited through a share swap arrangement, valuing the transaction at approximately ₹177.11 crore. This strategic move aims to strengthen its presence in the chemical industry through vertical integration.

Archit Organosys reported a 59% year-on-year increase in net profit for FY26, reaching ₹803.21 lakh. The chemical manufacturer saw total income grow by 11.77% to ₹14,383.71 lakh, reflecting improved operational performance and cost management.

The Board of Directors has recommended a final dividend of ₹1 per equity share, representing a 10% payout on the face value of ₹10. This marks a step-up from the previous year’s dividend of ₹0.50 per share.

Financial Performance

Revenue from operations stood at ₹14,095.25 lakh for the fiscal year ended March 31, 2026, compared to ₹12,559.92 lakh in FY25. The company managed to expand its profit before tax (PBT) to ₹1,099.25 lakh, up from ₹753.89 lakh in the prior year.

Operating costs rose to ₹13,055.64 lakh from ₹11,857.33 lakh, while financial expenses declined slightly to ₹228.82 lakh from ₹257.98 lakh.

What the Numbers Show

The divergence between revenue growth and profit expansion indicates improved operating leverage. While top-line growth was modest at 11.77%, the bottom line accelerated significantly due to a combination of lower financial costs and controlled operational expenses relative to income. The effective tax rate decreased to 26.93% from 33.00% in the previous year, further supporting the net profit margin expansion.

Corporate Governance and Strategy

The company’s paid-up equity share capital remained unchanged at ₹20.52 crore. During the year, there were changes in key managerial personnel, with Anilkumar G. Patel appointed as Chief Financial Officer and Chirag Chouhan as Company Secretary.

The Board highlighted confidence in future performance, citing opportunities in the specialty chemicals boom and expanding export markets. The company continues to focus on technology absorption and energy conservation to maintain competitive advantage in the chemical manufacturing sector.